Ann Dermatol.  2013 May;25(2):252-254. 10.5021/ad.2013.25.2.252.

Successful Treatment with Tacrolimus in a Case of the Glucocorticoid-Dependent Recurrent Cutaneous Eosinophilic Vasculitis

• Sugiyama M
• Nozaki Y
• Ikoma S
• Kinoshita
• Funauchi M

• KMID: 2171803
• DOI: http://doi.org/10.5021/ad.2013.25.2.252

Abstract

No abstract available.

MeSH Terms

Eosinophils
Tacrolimus
Vasculitis
Tacrolimus

Figure

• 

  Fig. 1 Purpuric papules and plaques on the palm.

• 

  Fig. 2 Histopathological findings of purpuric papules: biopsy revealed inflamed small dermal vessels with eosinophil-predominant infiltration (H&E, ×400).

Reference

1. Chen KR, Pittelkow MR, Su D, Gleich J, Newman W, Leiferman KM. Recurrent cutaneous necrotizing eosinophilic vasculitis. A novel eosinophil-mediated syndrome. Arch Dermatol. 1994. 130:1159–1166.

2. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008. 9:635–643.

3. Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007. 19:238–245.

4. Ehrchen J, Sunderkotter C, Luger T, Steinhoff M. Calcineurin inhibitors for the treatment of atopic dermatitis. Expert Opin Pharmacother. 2008. 9:3009–3023.

5. Sakuma-Oyama Y, Nishibu A, Oyama N, Saito M, Nakamura K, Kaneko F. A case of recurrent cutaneous eosinophilic vasculitis: successful adjuvant therapy with suplatast tosilate. Br J Dermatol. 2003. 149:901–903.

6. Hayashi M, Kawaguchi M, Mitsuhashi Y, Suzuki T. Case of hypereosinophilic syndrome with cutaneous necrotizing vasculitis. J Dermatol. 2008. 35:229–233.

7. Rolfe FG, Valentine JE, Sewell WA. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription. Am J Respir Cell Mol Biol. 1997. 17:243–250.

8. Mori A, Suko M, Kaminuma O, Inoue S, Ohmura T, Hoshino A, et al. IL-2-induced IL-5 synthesis, but not proliferation, of human CD4+ T cells is suppressed by FK506. J Immunol. 1997. 158:3659–3665.

9. Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol. 2004. 114:887–895.

10. Park CW, Lee BH, Han HJ, Lee CH, Ahn HK. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol. 2005. 152:1173–1181.